These findings explain why ESCC cells have much fewer NOTCH1 mutations than normal and precancerous epithelium, reveal a novel mechanism for Notch-signaling to drive tumor angiogenesis via the NOTCH1–USP5–STAT3 axis, and open a potential new avenue for anti-tumor angiogenesis therapy. This evidence concerns the gene STAT3 and neoplasm.